Do you have your own idea?
If you need elements of answer, we suggest reading the very exhaustive review by Musga Qureischi , Julia Mohr , Estibaliz Arellano , Sarah Elspeth Knudsen , Farrukh Vohidovn and Andoni Garitano published in the international review of cell and molecularbiology*.
in-vitro transcribed (IVT) mRNA is translated in the cytoplasm after transfection into cells, can encode virtually any target protein and has several advantages:
– Compared to DNA: it does not enter the nucleus, which avoids its integration into the genome and the risk for insertional mutagenesis
– Compared to recombinant proteins: its large-scale production is less complex
The review discusses the chemical modifications of IVT mRNA and highlights numerous preclinical and clinical applications including:
- Vaccines for cancer and infectiousdiseases
- Cancer immunotherapy
- Protein replacement
- Geneediting
- cellCreprogramming
We at Lifency congratulate the authors on their very interesting contribution and support the scientific and medical communities in their continuous and sustained efforts to identify novel therapeutic solutions
*Qureischi M, Mohr J, Arellano-Viera E, Knudsen SE, Vohidov F, Garitano-Trojaola A. mRNA-based therapies: Preclinical and clinical applications. Int Rev Cell Mol Biol. 2022;372:1-54. doi: 10.1016/bs.ircmb.2022.04.007. Epub 2022 Jun 3. PMID: 36064262. pharmaceuticalindustry